8 terminated. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 8 |
| Phase 1 | 1 | Terminated 1 |
Follow Arthralgia: new trials by email Literature Review of Arthralgia trials Research Report on Arthralgia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Methotrexate for Immune Related Arthritis or Arthralgias (IMPACT 2.1) Methotrexate - Arthritis, Arthralgia | Phase 2 | Terminated | AHS Cancer Control Alberta | 27 | 2024-08-12 | 2026-01-06 |
| Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis IHL-675A, Cannabidiol, Hydroxychloroquine - Rheumatoid Arthritis | Phase 2 | Terminated | Incannex Healthcare Ltd | 20 | 2023-11-22 | 2026-03-27 |
| A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) canakinumab, LNA043, Placebo to canakinumab - Knee Osteoarthritis | Phase 2 | Terminated | Novartis Pharmaceuticals | 23 | 2021-08-27 | 2025-10-24 |
| Resveratrol Trial for Relief of Pain in Pseudoachondroplasia resveratrol, Placebo - Pseudoachondroplasia | Phase 2 | Terminated | The University of Texas Health Science Center, Houston | 6 | 2019-06-29 | 2022-12-09 |
| Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease Calcium DTPA, Zinc DTPA - Headache, Cognitive Disturbance | Phase 1 / Phase 2 | Terminated | University of North Carolina, Chapel Hill | 1 | 2016-10-01 | 2018-04-06 |
| Safety Study of Renal Function in Patients With Chronic Kidney Failure Taking Lumiracoxib or Diclofenac for Arthralgia Lumiracoxib, Diclofenac - Kidney Failure, Chronic, Arthralgia | Phase 2 | Terminated | Hospital Central Sur de Pemex | 28 | 2012-01-01 | 2013-02-13 |
| A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis Oxycodone CR (standard pain medication), JNJ-42160443, Placebo - Osteoarthritis, Osteoarthritis, Knee | Phase 2 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 196 | 2010-04-20 | 2020-03-11 |
| A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain JNJ-42160443, Placebo - Osteoarthritis, Osteoarthritis, Hip | Phase 2 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 467 | 2009-09-16 | 2020-03-11 |
Osteoarthritis (3) · Osteoarthritis, Knee (3) · Pain (3) · Arthritis (2) · Arthritis, Rheumatoid (1) · Cognition Disorders (1) · Fatigue (1) · Headache (1) · Hyperpigmentation (1) · Kidney Failure, Chronic (1) · Osteoarthritis, Hip (1) · Pseudoachondroplasia (1)
Joint Diseases (8) · Musculoskeletal Diseases (8) · Neurologic Manifestations (8) · Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (8) · Pain (5) · Rheumatic Diseases (4) · Arthritis (3) · Skin and Connective Tissue Diseases (2) · Autoimmune Diseases (1) · Chronic Disease (1) · Connective Tissue Diseases (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
fulranumab (2) · Cannabidiol (1) · Diclofenac (1) · Hydroxychloroquine (1) · Methotrexate (1) · Pentetic Acid (1) · Resveratrol (1) · canakinumab (1) · lumiracoxib (1)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · AHS Cancer Control Alberta (1) · Hospital Central Sur de Pemex (1) · Incannex Healthcare Ltd (1) · Novartis Pharmaceuticals (1) · The University of Texas Health Science Center, Houston (1) · University of North Carolina, Chapel Hill (1)
United States (5) · Canada (3) · Poland (2) · Australia (1) · Czechia (1) · Estonia (1) · Hungary (1) · Latvia (1) · Mexico (1) · South Korea (1)
Alejandro Arce-Salinas, M.D. (1) · Carlos Molina-Calzada, M.D. (1) · Karen Posey, PhD (1) · Michael Kolinsky (1) · Richard Semelka, MD (1) · Stephen Hall, Prof. (1)
2009 (2)